Table 2 Overview of anti-IgE and ionomycin-induced release of histamine (ng/ml), LTC4/LTD4/LTE4 (ng/ml) and PGD2 (pg/ml) after 30 minutes in the nasal polyp (n = 8) and inferior turbinate group (n = 8).
From: Enhanced release of IgE-dependent early phase mediators from nasal polyp tissue
| Â | Histamine (ng/ml | LTC4/LTD4/LTE4 (ng/ml) | PGD2 (pg/ml) |
|---|---|---|---|
Nasal polyps | Â | Â | Â |
RPMI | 24.1 (15.1–32.6) | 0.0815 (0.048–0.11) | 109 (66.5–221) |
Versus | P < 0.01 | P < 0.01 | P < 0.01 |
Anti-igE 10 μg/ml | 43.2 (28.1–55.5) | 0.469 (0.348–0.816) | 1960 (1518–4544) |
Versus | P < 0.01 | P < 0.01 | P < 0.01 |
Anti-IgE 30 μg/ml | 63.6 (44.8–75.5) | 0.675 (0.561–1.21) | 4949 (2991–6152) |
Ionomycin 10 μM | 130 (77.5–135) | 3.40 (1.80–5.37) | 2717 (1364–4298) |
Versus baseline | P < 0.01 | P < 0.01 | P < 0.01 |
Inferior turbinates | Â | Â | Â |
RPMI | 8.5 (5.6–12.9) | 0.036 (0.016–0.0395) | 58.6 (40.2–88.2) |
Versus | P < 0.01 | P < 0.01 | P < 0.01 |
Anti-igE 10 μg/ml | 16.2 (12.0–20.2) | 0.0655 (0.038–0.181) | 840 (492–1269) |
Versus | P < 0.05 | P = 0.44 | P < 0.05 |
Anti-IgE 30 μg/ml (n = 6) | 28.1 (21.8–31.7) | 0.0715 (0.058–0.331) | 1669 (1311–1732) |
Ionomycin 10 μM | 27.6 (22.3–45.5) | 0.361(0.24–0.525) | 967 (548–1373) |
Versus baseline | P < 0.01 | P < 0.01 | P < 0.01 |